Yan Wang1, Jichao Jiao2, Daohai Wang3, Jingchao Song4, Kejun Huang1. 1. Department of Cardiology, Henan Provincial Chest Hospital Henan, China. 2. Department of Neurosurgery, The 7th People's Hospital of Zhengzhou Zhengzhou, Henan, China. 3. Department of Gsatroenterology, Henan Tumor Hospital Zhengzhou, Henan, China. 4. Department of Cardiac Surgery, Henan Provincial Chest Hospital Henan, China.
Abstract
OBJECTIVE: This study was designed to determine the effects of ticagrelor on the proliferation and apoptosis of and inflammatory factors in human aortic vascular smooth muscle cells (HAVSMCs). METHODS: A total of 20 patients who were first diagnosed with coronary heart disease (CHD) from August 2020 to March 2021 and 20 healthy adults were enrolled into the study. Oxidized low-density lipoprotein (ox-LDL) and different concentrations of ticagrelor were applied in the treatment of HAVSMCs, and then the cell proliferation and apoptosis and the expression of apoptosis-related proteins, inflammatory factors, and IκBα in them were determined. RESULTS: Compared with the ox-LDL group, the OD value was significantly increased after ticagrelor treatment, and the apoptosis rate was significantly reduced (P<0.05); compared with the ox-LDL group, the B lymphoma-2 (Bcl-2) protein, IκB, KCNQ1OT1 expression in the ticagrelor group increased significantly, Bcl-2-associated X protein (Bax), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) expression decreased significantly (P<0.05); The expression of serum KCNQ1OT1 in patients with coronary heart disease was significantly higher than that in healthy individuals (P<0.05). CONCLUSION: Ticagrelor may regulate the expression of lncRNA KCNQ1OT1 and up-regulate the expression of IκBα to promote proliferation and anti-apoptosis, so as to prevent ox-LDL from oxidative damage to HAVSMCs. AJTR
OBJECTIVE: This study was designed to determine the effects of ticagrelor on the proliferation and apoptosis of and inflammatory factors in human aortic vascular smooth muscle cells (HAVSMCs). METHODS: A total of 20 patients who were first diagnosed with coronary heart disease (CHD) from August 2020 to March 2021 and 20 healthy adults were enrolled into the study. Oxidized low-density lipoprotein (ox-LDL) and different concentrations of ticagrelor were applied in the treatment of HAVSMCs, and then the cell proliferation and apoptosis and the expression of apoptosis-related proteins, inflammatory factors, and IκBα in them were determined. RESULTS: Compared with the ox-LDL group, the OD value was significantly increased after ticagrelor treatment, and the apoptosis rate was significantly reduced (P<0.05); compared with the ox-LDL group, the B lymphoma-2 (Bcl-2) protein, IκB, KCNQ1OT1 expression in the ticagrelor group increased significantly, Bcl-2-associated X protein (Bax), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) expression decreased significantly (P<0.05); The expression of serum KCNQ1OT1 in patients with coronary heart disease was significantly higher than that in healthy individuals (P<0.05). CONCLUSION: Ticagrelor may regulate the expression of lncRNA KCNQ1OT1 and up-regulate the expression of IκBα to promote proliferation and anti-apoptosis, so as to prevent ox-LDL from oxidative damage to HAVSMCs. AJTR
Authors: Rongxia Liu; Elke H Heiss; Birgit Waltenberger; Tina Blažević; Daniel Schachner; Baohong Jiang; Vladimir Krystof; Wanhui Liu; Stefan Schwaiger; Luis M Peña-Rodríguez; Johannes M Breuss; Hermann Stuppner; Verena M Dirsch; Atanas G Atanasov Journal: Mol Nutr Food Res Date: 2018-03-30 Impact factor: 5.914